Semaglutide has been approved by the FDA for the treatment of obesity in adults and is written into the U.S. Weight Loss Drug Guide, and as of June 25, 2024, there is a nationally approved indication for the use of semaglutide in certain overweight and obese patients.

Simeglutide is used abroad as an adjunct to a low-calorie diet and increased exercise for the treatment of patients with a body mass index (BMI) ≥ 27 kg/m2 in combination with at least one obesity complication, or in patients with simple obesity with a BMI ≥ 30 kg/m2.

In our country listed Ozempic currently only hypoglycemic and reduce the risk of cardiovascular adverse events with cardiovascular risk of type 2 diabetes patients with the indication, can not be used purely for weight loss, with this drug to lose weight in our country at present still belongs to the superscriptive use of the drug, is not recommended for weight loss.

This simeglutide  can be used for weight management under physician supervision, specifically, this approved indication is for overweight and obese patients with an initial BMI greater than or equal to 30 kg/m2; or between 27 kg/m2 and 30 kg/m2 with at least one weight-related comorbidity.

In addition, other once-a-week glucose-lowering medications such as dulaglutide are not currently recommended in our country solely for weight loss.

The information is from the Internet and is for reference only.